Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid; filamentous haemagglutinin; haemophilus influenza type b polysaccharide (polyribosylribitol phosphate) conjugated to 22 - 36 μg tetanus protein (prp-t); hepatitis b surface antigen; pertussis toxoid; poliovirius (inactivated) type 1 (mahoney); poliovirus (inactivated) type 2 (mef-1); poliovirus (inactivated) type 3 (saukett); tetanus toxoid - injection, suspension - diphtheria toxoid 30 lf (>= 20 iu)/0.5 ml; filamentous haemagglutinin 25 μg/0.5 ml; haemophilus influenza type b polysaccharide (polyribosylribitol phosphate) conjugated to 22 - 36 μg tetanus protein (prp-t) 12 μg/0.5 ml; hepatitis b surface antigen 10 μg/0.5 ml; pertussis toxoid 25 μg/0.5 ml; poliovirius (inactivated) type 1 (mahoney) 40 du/0.5 ml; poliovirus (inactivated) type 2 (mef-1) 8 du/0.5 ml; poliovirus (inactivated) type 3 (saukett) 32 du/0.5 ml; tetanus toxoid 10 lf (>= 40 iu)/0.5 ml

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: zuellig pharma corporation - diphtheria, tetanus, pertussis (acellular component), hepatitis b, poliomyelitis (inactivated) and haemophilus influenzae type b conjugate vaccine (adsorbed) - suspension for injection (im) - formulation: each dose (0.5 ml) contains: diphtheria toxoid' tetanus toxoid ' bordetella pertussis antigen pertussis toxoid' filamentous hemagglutinin' poliovirus (inactivated)2.3 type i (mahoney) strain nlt 20 iu nlt 40 iu hepatitis b surface antigen haemophilus influenzae type b polysaccharide phosphate) 10 mcg (polyribosylribitol 12 mcg conjugate to tetanus protein 22-36 mcg 25 mcg 25 mcg 40 d antigen units type ii (mef-1) strain" type iii (saukett) strain1 8 d antigen units 32 d antigen units 'adsorbed on aluminium hydroxide, hydrated (al(oh)3) 2produced in yeast cells (saccharomyces cerevisiae) by recombinant dna technology 3adsorbed on aluminium phosphate (aipo4) *propagated in vero cells

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu; haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)); hepatitis b virus surface antigen 10ug; pertussis filamentous haemagglutinin 25ug (adsorbed); pertussis toxoid, adsorbed 25ug; polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (mef-1); polio virus type 3 32 dagu (saukett); tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu - suspension for injection - active: diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)) hepatitis b virus surface antigen 10ug pertussis filamentous haemagglutinin 25ug (adsorbed) pertussis toxoid, adsorbed 25ug polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (mef-1) polio virus type 3 32 dagu (saukett) tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu excipient: aluminium hydroxide amino acids dibasic sodium phosphate monobasic potassium phosphate sucrose trometamol water for injection - hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive infections caused by haemophilus influenzae type b. use of this vaccine should be in accordance with the national recommendation as per the current immunisation handbook.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (prefilled syringe) diphtheria toxoid; (prefilled syringe) filamentous haemagglutinin; (prefilled syringe) pertussis toxoid; (prefilled syringe) poliovirus (inactivated) - type 1 (mahoney); (prefilled syringe) poliovirus (inactivated) - type 2 (mef-1); (prefilled syringe) poliovirus (inactivated) - type 3 (saukett); (prefilled syringe) tetanus toxoid; (vial) haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein; (vial) tetanus protein (prp-t) - injection, powder, for suspension - (prefilled syringe) diphtheria toxoid min. 20 iu (30 lf)/0.5 ml; (prefilled syringe) filamentous haemagglutinin 25 μg/0.5 ml; (prefilled syringe) pertussis toxoid 25 μg/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 1 (mahoney) 29 du/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 2 (mef-1) 7 du/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 3 (saukett) 26 du/0.5 ml; (prefilled syringe) tetanus toxoid min. 40 iu (10 lf) /0.5 ml; (vial) haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein 10 μg/0.5 ml; (vial) tetanus protein (prp-t) 18 - 30 μg/0.5 ml

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

poliovirus (inactivated) type 1 (mahoney), filamentous haemagglutinin [bordetella pertussis antigens], poliovirus (inactivated) type 2 (mef-1), poliovirus (inactivated) type 3 (saukett), hepatitis b surface antigen, pertussis toxoid [bordetella pertussis antigens], tetanus toxoid not less than, diphtheria toxoid not less than, haemophilus influenzae type b polysaccharide (polyribosylribitol phoshate) conjugated to tetanus protein 22-36 micrograms -

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - diphtheria toxoid tetanus toxoid pertussis toxoid filamentous haemagglutinin (fha) pertactin polio virus type 1 inactivated polio virus type 2 inactivated polio virus type 3 inactivated haemophilus influenzae type b capsular polysaccharide (prp) and tetanus toxoid tetanus vaccine adsorbed - %v/v

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - hepatitis a virus (inactivated) - injection - 50u/ml - hepatitis a virus (inactivated) 50u/ml

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid; filamentous haemagglutinin; hepatitis b surface antigen (purified); hib purified capsular polysaccharide bound to tetanus toxoid; pertactin (69 kda omp); pertussis toxoid; poliovirus type 1 (inactivated); poliovirus type 2 (inactivated); poliovirus type 3 (inactivated) - injection - min 30 iu/0.5 ml - diphtheria toxoid min 30 iu/0.5 ml; filamentous haemagglutinin 25 mcg/0.5 ml; hepatitis b surface antigen (purified) 10 mcg/0.5 ml; hib purified capsular polysaccharide bound to tetanus toxoid 10 mcg/0.5 ml; pertactin (69 kda omp) 8 mcg/0.5 ml; pertussis toxoid 25 mcg/0.5 ml; poliovirus type 1 (inactivated) 40 du/0.5 ml; poliovirus type 2 (inactivated) 8 du/0.5 ml; poliovirus type 3 (inactivated) 32 du/0.5 ml

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid (d); filamentous haemagglutinin (fha); hib purified capsular polysaccharide; pertactin (prn or 69kda outer membrane protein); pertussis toxoid (pt); polio virus type 1 (inactivated); polio virus type 2 (inactivated); polio virus type 3 (inactivated); tetanus toxoid (t) - injection - min 30iu/0.5ml - diphtheria toxoid (d) min 30iu/0.5ml; filamentous haemagglutinin (fha) 25mcg/0.5ml; hib purified capsular polysaccharide 10 mcg/0.5 ml; pertactin (prn or 69kda outer membrane protein) 8mcg/0.5ml; pertussis toxoid (pt) 25mcg/0.5ml; polio virus type 1 (inactivated) 40du/0.5ml; polio virus type 2 (inactivated) 8du/0.5ml; polio virus type 3 (inactivated) 32du/0.5ml; tetanus toxoid (t) min 40iu/0.5ml

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - hepatitis a virus (inactivated) - injection - 25 u/0.5 ml - hepatitis a virus (inactivated) 25 u/0.5 ml